A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

Kezar Life Sciences, Inc.25 enrolled

Overview

This was a Phase 2 randomized, double-blind, placebo-controlled, crossover, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with KZR-616 in patients with active polymyositis (PM) or dermatomyositis (DM). Patients were evaluated for eligibility during the Screening Period. Eligible patients were stratified by diagnosis of DM or PM and randomized 1:1 to Arm A or Arm B of the study. During the 32-week treatment period, patients received study drug subcutaneously (SC) once weekly with 2 treatment periods of 16 weeks each. This study was conducted on an outpatient basis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Polymyositis Dermatomyositis

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Adult patients at least 18 years of age 2. Body Mass Index (BMI) of 18 to 40 kg/m\^2 3. Diagnosis of probable or definite DM or PM by the 2017 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Classification Criteria 4. Must have their data reviewed by an adjudication committee to confirm eligibility unless at least 1 of the following is present: 1. Muscle biopsy with evidence of active myositis within the last 6 months prior to or at Screening 2. Electromyography or magnetic resonance imaging with evidence of active myositis within the last 6 months prior to Screening 3. A creatine kinase (CK) ≥4 × upper limit of normal (ULN). 5. Must have demonstrable muscle weakness as measured by the Manual Muscle Testing-8 muscle Groups (MMT-8) with a score ≥80/150 but ≤136/150 units and any 2 of the following: 1. Physician Global Assessment (MDGA) visual analog scale (VAS) ≥2 cm 2. Patient Global Assessment of Disease Activity (PtGADA) VAS ≥2 cm 3. At least one muscle enzyme laboratory measurement ≥1.3 × ULN 4. Myositis Disease Activity Assessment Tool (MDAAT) Extramuscular Global Activity VAS ≥1 cm. 6. Documented inadequate response OR have demonstrated documented toxicity or intolerance to prior standard of care therapies 7. Has had age-appropriate cancer screening that is up to date and negative for evidence of malignancy as per local standard of care Exclusion Criteria: 1. Has significant muscle damage or has a muscle damage VAS score ≥5 cm on the MDI 2. Any other form of myositis or myopathy other than PM or DM 3. Any condition that precludes the ability to quantitate muscle strength 4. Has severe interstitial lung disease or has a pulmonary damage VAS score ≥5 cm on the Myositis Damage Index (MDI) 5. Presence of autoinflammatory disease 6. Use of nonpermitted medications or treatments within the specified washout periods prior to screening 7. Patient has had recent serious or ongoing infection, or risk for serious infection 8. Any of the following laboratory values at Screening: 1. Estimated glomerular filtration rate \<45 mL/min 2. Hemoglobin \<10 g/dL 3. White blood cell (WBC) count \<3.0 × 10\^9/L 4. Absolute neutrophil count (ANC) \<1.5 × 10\^9/L (1500/mm\^3) 5. Platelet count \<100 × 10\^9/L 6. Serum AST or serum ALT \>2.5 × ULN (unless considered consistent with muscle origin) 7. Serum alkaline phosphatase \>2.5 × ULN 8. Total bilirubin \>1.5 × ULN (3 × ULN for patients with documented Gilbert's syndrome) 9. Thyroid stimulating hormone outside of the central laboratory normal range 10. Immunoglobulin G (IgG) \<500 mg/dL. 9. Presence of New York Heart Association Class III or IV heart failure, or uncontrolled blood pressure, or prolonged QT interval 10. Major surgery within 12 weeks before Screening or planned during the study period 11. Clinical evidence of significant unstable or uncontrolled diseases 12. Any active or suspected malignancy, including myeloproliferative or lymphoproliferative disorder, or history of documented malignancy within the last 5 years before Screening or within 3 years of diagnosis of myositis, except appropriately excised and cured cervical carcinoma in situ or basal or squamous cell carcinoma of the skin

Locations (14)

KZR Research Site

Beverly Hills, California, United States

KZR Research Site

Orange, California, United States

KZR Research Site

Miami, Florida, United States

KZR Research Site

Atlanta, Georgia, United States

KZR Research Site

Kansas City, Kansas, United States

KZR Research Site

Baltimore, Maryland, United States

KZR Research Site

Ann Arbor, Michigan, United States

KZR Research Site

Great Neck, New York, United States

KZR Research Site

Duncansville, Pennsylvania, United States

KZR Research Site

Pittsburgh, Pennsylvania, United States

...and 4 more locations

Outcomes

Primary Outcomes

Mean Change in the Total Improvement Score (TIS) From Start to End of Zetomipzomib (KZR-616) Treatment Period

The primary efficacy endpoint was mean change from start to end of zetomipzomib (KZR-616) Treatment Periods in the Total Improvement Score (TIS), which ranges from 0 to 100 \[low of 0 to high of 100, where higher scores are better\]. Mean change in TIS was calculated by comparing the Baseline and post Baseline observations for patients in both KZR-616 treatment periods combined. Note: TIS scores for placebo treatment periods are presented in this outcome measure but were not included in the primary outcome measure analysis.